Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
interferon alfacon-1
- Development stage
- Phase 3
- Lead developer
- Amgen
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Administration
- Subcutaneous
01
Overview
Interferon alfacon-1 is a non-naturally occurring recombinant type I alpha interferon engineered to contain the most frequently occurring amino acids among human IFN-alpha subtypes, forming a "consensus" molecule. It acts as a cytokine with antiviral and immunomodulatory properties. Its primary mechanism involves binding to type I interferon receptors (IFNAR1 and IFNAR2), activating Janus kinases (JAK1 and TYK2), which then phosphorylate STAT transcription factors. This leads to the expression of numerous genes involved in antiviral defense, inhibition of cellular growth, modulation of immune responses, and increased cytotoxicity of lymphocytes against target cells. Interferon alfacon-1 was developed for the treatment of chronic hepatitis C infection in patients who were either naïve or had not responded to previous therapies with other forms of interferons[1][2][4]. The drug demonstrated higher antiviral efficacy compared to some other alpha-interferons but has been withdrawn from certain markets due to economic reasons following company mergers[1].
- Brand names
- Infergen
- Other names
- consensus interferonconsensus interferon-alpha
02
Targets
IFNAR2 (Interferon alpha/beta receptor subunit 2)IFNAR1 (Interferon alpha/beta receptor 1)
Beyond the preview
Go deeper on interferon alfacon-1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on interferon alfacon-1.